Status:
UNKNOWN
Pheno- & Genotyping POF (WHO III)
Lead Sponsor:
UMC Utrecht
Collaborating Sponsors:
Erasmus Medical Center
Medical Center Alkmaar
Conditions:
Premature Ovarian Failure (POF)
Incipient Ovarian Failure
Eligibility:
FEMALE
12+ years
Brief Summary
This study focuses on the phenotyping and genotyping of women with hypergonadotropic ovarian dysfunction (WHO III status).
Detailed Description
First goal of the study is to phenotype patiens with hypergonadotropic ovarian dysfunction (WHO III) adequately. This group includes women with premature ovarian failure (POF), incipient ovarian failu...
Eligibility Criteria
Inclusion
- POF; defined as secondary amenorrhea before 40 years of age and basal FSH \> 40 IU/L
- Incipient ovarian failure; defined as normo-ovulatory cycles, raised basal FSH \> 12 IU/L
- Poor response patients; defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 IU gonadotropins or cancellation in case of absent follicle growth
- Women with early menopause (between 40-45 years)
- Hypergonadotropic primary amenorrhea
Exclusion
- Primary amenorrhea with early development disorders causing absence of ovaries and Swyer syndrome (XY)
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT01411644
Start Date
January 1 2005
End Date
June 1 2020
Last Update
December 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMC Utrecht
Utrecht, Netherlands, 3508 GA